Figure 3.

Comparison of cell percentages of distinct NK maturation subsets within the bone marrow microenvironment of NBM, MDS, and AML cases. (A) Percentage of bone marrow CD56^bright CD94^hi CD16^- CD57^- immature NK cells in normal bone marrow (NBM, n = 30), myelodysplastic syndromes (MDS, n = 25), and acute myeloid leukemias (AML, n = 8) cases. Bars represent the mean ± SEM (*P < 0.05, ns, not significant; one-tailed unpaired t-test). (B) Percentage of bone marrow CD56^dim CD94^med CD16⁺ CD57^- mature NK cells in NBM (n = 30), MDS (n = 24), and AML (n = 8) cases. Bars represent the mean ± SEM (*P < 0.05, ns, not significant; one-tailed unpaired t-test). (C) Percentage of bone marrow CD56^dim CD94^low CD16⁺ CD57⁺ hypermature NK cells in NBM (n = 30), MDS (n = 25), and AML (n = 8) cases. Bars represent the mean ± SEM (ns, not significant; one-way ANOVA followed by Tukey’s Multiple Comparison test).